Oct 27 (Reuters) - Merck & Co Inc MRK.N on Tuesday reported a 54.7% rise in third-quarter profit, helped by strong sales of blockbuster cancer drug Keytruda and rebound in sales of its key drugs.
The company's net income rose to $2.94 billion, or $1.16 per share, in the third quarter ended Sept. 30, from $1.90 billion, or $0.74 per share, a year earlier.
(Reporting Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)
((firstname.lastname@example.org; +91 8061822700;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.